News

METiS Pharmaceuticals Welcomes Mark Herbert as CBO

METiS Pharmaceuticals Welcomes Mark Herbert as CBO

Mark Herbert Joins METiS Pharmaceuticals as Chief Business Officer

In a significant development within the biotechnology industry, METiS Pharmaceuticals has appointed Mark Herbert as their Chief Business Officer (CBO). This move underscores the company's commitment to advancing its innovative drug delivery technologies. Mark's extensive background and vision for business growth are set to play a pivotal role in METiS' objectives.

Years of Expertise and Proven Track Record

Mark Herbert comes to METiS with over two decades of experience in the biotech and pharmaceutical sectors, having acquired a remarkable reputation for driving business development and forging essential partnerships. Before joining METiS, Mark held the position of President at Arcturus Therapeutics. There, he was crucial in establishing strategic alliances with leading companies in the industry, generating substantial partnership value exceeding $2 billion. His experience also includes roles such as Vice President of Business Development at Varda Space Industries and Chief Business Officer at Scientist.com.

Welcoming Leadership at METiS

Dr. Chris Lai, Co-founder and CEO of METiS Pharmaceuticals, expressed enthusiasm about Mark’s arrival. "We are excited to welcome Mark Herbert to METiS," he stated. "His unparalleled leadership skills and extensive knowledge of the biotech sector will be crucial as we aim to enhance our partnerships and seek new business opportunities. Mark’s expertise aligns perfectly with our vision for growth and innovation.”

Strategic Growth for the Future

The dynamic advancements in drug delivery technologies at METiS Pharmaceuticals are noteworthy. With Mark Herbert's appointment, the company is poised for a new phase of development, focusing on expanding its reach and efficacy in a competitive market. Dr. Hongmin Chen, Co-founder and CRDO, echoed this sentiment, highlighting how Mark's global perspective will be integral to creating strategic partnerships that bring METiS' pioneering technologies to patients worldwide.

A Commitment to Innovation

Mark Herbert himself expressed his excitement about joining METiS, stating, "Joining the talented team at METiS Pharmaceuticals is a tremendous honor. I look forward to working closely with the team to advance our cutting-edge nucleic acid and drug delivery technologies, drive innovation, and expand our global partnerships. METiS is at the forefront of using AI to revolutionize drug delivery, and I'm thrilled to be part of this exciting journey." This commitment to using AI in their technologies sets METiS apart as they strive to redefine how drugs are delivered to patients.

Transformative Technology in Drug Delivery

Over the years, METiS Pharmaceuticals has achieved remarkable progress in developing AI-driven lipid nanoparticle (LNP) delivery systems. These systems have shown unparalleled efficacy in targeted nano delivery, particularly for organs such as the liver and lungs, reporting results that indicate up to 20 times greater success rates in treating liver cancer and lung tumors compared to existing standards. The company has also fostered collaborations with more than 20 leading global pharmaceutical and biotech firms, amplifying their impact on the healthcare landscape.

Mark's leadership signifies METiS' dedication to pushing boundaries in drug delivery methods and exemplifying their mission to provide transformative therapies for patients globally.

About METiS Pharmaceuticals

Established in 2020, METiS Pharmaceuticals is an AI-driven biotech company that specializes in improving drug delivery systems. Their innovative approach harnesses AI, machine learning, and quantitative modeling to transform drug delivery and development processes. METiS is paving the way for programmable nucleic acid therapeutics and next-generation RNA delivery to meet unmet medical needs, striving to provide groundbreaking treatments for patients worldwide.

Frequently Asked Questions

Who is Mark Herbert?

Mark Herbert is the newly appointed Chief Business Officer of METiS Pharmaceuticals, bringing extensive experience in the biotech industry.

What is METiS Pharmaceuticals known for?

METiS Pharmaceuticals specializes in innovative drug delivery technologies driven by AI.

What significant achievements does METiS Pharmaceuticals have?

The company has developed AI-driven lipid nanoparticle delivery systems, achieving breakthroughs in targeted drug delivery.

Where did Mark Herbert work prior to joining METiS?

Prior to METiS, Mark Herbert served as President of Arcturus Therapeutics and held various key roles in other biotech companies.

How does METiS plan to grow in the future?

With Mark Herbert's leadership, METiS aims to expand its partnerships and continue advancing innovative technologies in drug delivery.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenPower Motor Company Aims for Enhanced Growth by Delisting

Updated Category News Views 218

GreenPower Motor Company Announces Delisting Decision GreenPower Motor Company Inc. (NASDAQ: GP) is making a significant move in its growth strategy. The company, which is renowned for manufacturing and distributing all-electric vehicles tailored for medium and heavy-duty applications, has decided to voluntarily delist its shares from the TSX Venture Exchange (the...

Continue Reading
VEON Announces Q4 2024 Trading Update Conference Details

Updated Category News Views 264

VEON Announces Q4 2024 Trading Update Conference Details Dubai – VEON Ltd. (NASDAQ: VEON), a prominent digital operator, has confirmed the upcoming release of significant financial information regarding its fourth quarter and full year ending December 31, 2024. This update will occur around 10:00 GST (2:00 EST) on March 20, 2025. In addition to the financial update,...

Continue Reading
Netcapital's Revenue Fraud Scandal Hits Investor Confidence

Updated Category News Views 206

The Rise and Fall of Netcapital: A Troubling Drop Netcapital Inc. (NASDAQ: NCPL) has found itself in hot water with investors after revelations of a wild scheme to fluff up its revenue figures. It’s like watching a house of cards crumble — and investors are left holding the bag. From December 15, 2021, through September 3, 2026, a slew of misinformation allegedly...

Continue Reading
Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return

Updated Category News Views 394

Honoring Lt. Thomas V. Kelly Jr.: A Hero's Long-Awaited Return This Memorial Day weekend marks a significant moment in history as the San Francisco East Bay welcomes back a hero after eight decades. The community prepares for a heartfelt homecoming for 2nd Lt. Thomas V. Kelly Jr., who served valiantly as a bombardier during World War II. A Journey Through History Born in...

Continue Reading
TOMY's Zoids Ultrasaurus: Gun for Nostalgia and Growth

Updated Category News Views 28

Unlocking the Power of Nostalgia with TOMY's Ultrasaurus Nostalgia isn't just an emotion; it's a powerful force that can drive sales like nobody's business, and TOMY Company knows this well. They're rolling out the big guns—literally—by adding the animated series' beloved Gravity Cannon to their new AZ-17DX Ultrasaurus model. How's that for a hook? The Gravity Cannon...

Continue Reading